Biosimilar Antibodies

Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb – Research Grade, ProteoGenix, PX-TA1590

Description of Glofitamab Biosimilar - Anti-CD3E, MS4A1 mAb - Research Grade Introduction to Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb is a novel biosimilar antibody that targets the CD3E and MS4A1 proteins. This antibody has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various diseases. In this article, we will discuss the structure, activity, and potential applications of Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb in detail. Structure of Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb is a monoclonal antibody that is designed to mimic the structure and function of the original antibody, which targets CD3E and MS4A1 proteins. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains are further divided into four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains are responsible for binding to the target proteins, while the constant domains provide stability and effector functions. Activity of Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb has a dual mechanism of action, which makes it a promising therapeutic candidate. Firstly, it binds to CD3E, a protein that is expressed on the surface of T cells, leading to T cell activation and proliferation. This results in the destruction of target cells, such as cancer cells, by the activated T cells. Secondly, it binds to MS4A1, a protein that is expressed on the surface of B cells, leading to their depletion. This is particularly beneficial in diseases where B cells play a pathogenic role, such as autoimmune diseases. Potential Applications of Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various diseases. Some of the potential applications of this antibody are: 1. Cancer: CD3E is overexpressed on the surface of many types of cancer cells, making it an attractive target for cancer therapy. Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb has shown promising results in preclinical studies for the treatment of various types of cancer, including lymphoma, leukemia, and solid tumors. 2. Autoimmune diseases: MS4A1 is involved in the activation and survival of B cells, which play a pathogenic role in many autoimmune diseases. Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb has shown potential in preclinical studies for the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus. 3. Organ transplantation: CD3E is also expressed on the surface of T cells that are involved in organ rejection in transplant patients. Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb has the potential to prevent organ rejection by depleting these T cells. Conclusion Glofitamab Biosimilar – Anti-CD3E, MS4A1 mAb is a novel biosimilar antibody with a dual mechanism of action. It has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various diseases, including cancer, autoimmune diseases, and organ transplantation. Its unique structure and activity make it a promising therapeutic candidate, and further studies are needed to fully explore its potential applications.

Glutazumab Biosimilar – Research Grade, ProteoGenix, PX-TA2460-100

Golimumab Biosimilar – Anti-TNFA, TNF alpha mAb – Research Grade, ProteoGenix, PX-TA1129

Description of Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb - Research Grade General information on Anti-TNFA/TNF alpha(Homo sapiens) (Golimumab) Monoclonal Antibody Golimumab is a human IgG1 alpha monoclonal antibody, developped from genetically engineered mice immunized with human TNFalpha. Golimumab binds to and inhibits soluble and transmembrane human TNFalpha. Elevated TNFalpha is related to chronic inflammation. Therefore, golimumab can be used in adults,for the treatment of active rheumatoid arthritis (RA), active psoriatic arthritis ( PsA), active ankylosing spondylitis (AS), ulcerative colitis (UC). In the United States and Canada, golimumab is sold under the Simponi® brand. The FDA label includes a black box that warns of serious infections and malignant tumors.

Gosuranemab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1528-

Gremubamab Biosimilar – Anti-PcrV and Psl mAb – Research Grade, ProteoGenix, PX-TA1591

Description of Gremubamab Biosimilar - Anti-PcrV and Psl mAb - Research Grade Overview of Gremubamab Biosimilar as a Therapeutic Antibody Gremubamab biosimilar is a research-grade therapeutic antibody developed to target key virulence determinants of Pseudomonas aeruginosa , one of the most clinically relevant opportunistic bacterial pathogens. This monoclonal antibody is designed to recognize two major surface-associated factors: PcrV, a structural component of the Type III Secretion System (T3SS), and Psl, a critical exopolysaccharide involved in biofilm formation. By simultaneously addressing acute virulence and biofilm-associated persistence, Gremubamab biosimilar represents a valuable tool for translational and preclinical research focused on anti-infective antibody strategies. Structural Characteristics of the Anti-PcrV and Psl Monoclonal Antibody Gremubamab biosimilar is a full-length IgG monoclonal antibody produced using recombinant expression systems to ensure high batch-to-batch consistency. Structurally, it comprises two identical heavy chains and two identical light chains forming a Y-shaped immunoglobulin architecture typical of IgG antibodies. The antigen-binding fragments (Fab regions) are engineered to specifically recognize conserved epitopes on PcrV and Psl, while the Fc region retains the canonical IgG structure, enabling interaction with immune effector mechanisms in experimental models. As a research-grade biosimilar, its sequence and binding properties are designed to closely mimic those of the reference antibody, supporting reproducible comparative studies. Biological Activity and Mechanism of Action The biological activity of this therapeutic antibody lies in its dual targeting mechanism. Binding to PcrV interferes with the assembly and function of the T3SS needle tip complex, a critical structure required for the injection of cytotoxic effector proteins into host cells. This inhibition reduces bacterial cytotoxicity and attenuates acute virulence. In parallel, recognition of Psl exopolysaccharide disrupts biofilm-associated processes by impairing bacterial adhesion, aggregation, and surface persistence. Together, these activities allow researchers to study how antibody-mediated neutralization can modulate both planktonic and biofilm-associated phenotypes of P. aeruginosa . Applications in Research and Preclinical Studies Gremubamab biosimilar is widely used as a research-grade reagent in microbiology, immunology, and infectious disease research. Typical applications include in vitro neutralization assays, biofilm inhibition studies, flow cytometry (FACS) detection of Psl expression, and mechanistic investigations of T3SS regulation. It is also employed in animal infection models to explore antibody-based intervention strategies and to evaluate synergistic effects with antibiotics. As a biosimilar, it is particularly valuable for comparative studies aimed at understanding structure–function relationships and benchmarking novel anti- Pseudomonas antibodies. Relevance for Therapeutic Antibody Development Beyond its immediate research applications, Gremubamab biosimilar provides important insights into the development of next-generation therapeutic antibodies against bacterial pathogens. By targeting virulence rather than bacterial viability, this antibody supports alternative anti-infective strategies that may reduce selective pressure for antibiotic resistance. Its dual specificity toward PcrV and Psl also highlights the potential of multi-target antibody approaches to address complex infection dynamics involving both acute and chronic disease states. Conclusion In summary, Gremubamab biosimilar is a structurally well-defined, biologically active anti-PcrV and Psl monoclonal antibody that serves as a powerful research-grade therapeutic antibody model. Its dual mechanism of action and broad applicability make it a valuable asset for advancing fundamental research and supporting the development of innovative antibody-based anti-infective therapies.

Grisnilimab Biosimilar – Anti-CD7 mAb – Research Grade, ProteoGenix, PX-TA1672

Description of Grisnilimab Biosimilar - Anti-CD7 mAb - Research Grade Introduction Grisnilimab Biosimilar, also known as Anti-CD7 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody, Alemtuzumab. It is a promising drug candidate with potential applications in the treatment of various types of cancers and autoimmune disorders. Structure of Grisnilimab Biosimilar Grisnilimab Biosimilar is a recombinant humanized monoclonal antibody that has been designed to target the CD7 antigen. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions of the antibody are responsible for binding to the CD7 antigen, while the constant regions provide stability and effector functions. The heavy chains of Grisnilimab Biosimilar contain a hinge region, a CH1 domain, a CH2 domain, and a CH3 domain. The light chains consist of a variable domain and a constant domain. The variable regions of both the heavy and light chains are highly specific for the CD7 antigen, allowing Grisnilimab Biosimilar to bind to the target with high affinity and specificity. Mechanism of Action Grisnilimab Biosimilar works by binding to the CD7 antigen, which is found on the surface of T cells and natural killer (NK) cells. This binding triggers a series of events that lead to the destruction of these cells, ultimately resulting in the suppression of the immune response. When Grisnilimab Biosimilar binds to CD7, it activates the complement system, which is a part of the immune system that helps in the destruction of pathogens and abnormal cells. This leads to the formation of a membrane attack complex, which creates pores in the cell membrane of the target cells, causing them to lyse and die. Additionally, Grisnilimab Biosimilar also induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms involve the recruitment and activation of immune cells, such as macrophages and natural killer cells, to target and destroy the CD7-expressing cells. Applications of Grisnilimab Biosimilar The primary application of Grisnilimab Biosimilar is in the treatment of CD7-positive cancers, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. CD7 is highly expressed on the surface of these cancer cells, making them ideal targets for Grisnilimab Biosimilar. By binding to and destroying these cells, Grisnilimab Biosimilar can effectively inhibit the growth and spread of these cancers. In addition to cancer, Grisnilimab Biosimilar also has potential applications in the treatment of autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis. These conditions are characterized by an overactive immune response, which can be suppressed by targeting and destroying CD7-expressing immune cells. Research Grade Grisnilimab Biosimilar Grisnilimab Biosimilar is currently being developed as a research grade antibody, which is intended for use in laboratory research and preclinical studies. It is not yet approved for clinical use, but its potential therapeutic applications have generated significant interest in the scientific community. Conclusion In summary, Grisnilimab Biosimilar is a promising biosimilar to the therapeutic antibody, Alemtuzumab. Its specific structure and mechanism of action make it a potent anti-CD7 mAb with potential applications in the treatment of various cancers and autoimmune disorders. As research on Grisnilimab Biosimilar continues, it is expected to play a significant role in the development of new and improved treatments for these diseases.

Guselkumab Biosimilar – Anti-IL23A mAb – Research Grade, ProteoGenix, PX-TA1327

Description of Guselkumab Biosimilar - Anti-IL23A mAb - Research Grade General information on Anti-IL23A[Homo sapiens] (Guselkumab) Monoclonal Antibody Guselkumab is a human IgG1 lambda monoclonal antibody that targets interleukin-23. IL-23 is an inflammatory cytokine that is reponsible for the activation of the CD4+ T-helper (Th17) cell pathway in the inflammatory cascade that induces psoriatic plaque formation. Guselkumab has been used to treat psoriasis. It has been sold under the trade name Tremfya.

Hersintuzumab Biosimilar – Research Grade, ProteoGenix, PX-TA2462-100

Ianalumab Biosimilar – Anti-TNFRSF13C, CD268 mAb – Research Grade, ProteoGenix, PX-TA1480

Description of Ianalumab Biosimilar - Anti-TNFRSF13C, CD268 mAb - Research Grade Introduction Ianalumab Biosimilar, also known as Anti-TNFRSF13C or CD268 monoclonal antibody, is a research grade therapeutic antibody that has been developed as a biosimilar to the existing drug, Belimumab. This antibody targets the TNFRSF13C protein, also known as CD268, which plays a crucial role in the regulation of the immune system. In this article, we will discuss the structure, activity, and potential applications of Ianalumab Biosimilar. Structure of Ianalumab Biosimilar Ianalumab Biosimilar is a monoclonal antibody, which means it is produced from a single type of immune cell. It is a fully humanized antibody, meaning it is derived from human cells and therefore has a lower risk of causing an immune response in patients. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, held together by disulfide bonds. The variable regions of the antibody, which are responsible for binding to the target protein, are highly specific for the TNFRSF13C protein. This specificity is achieved through the process of genetic engineering, where the antibody is produced by inserting the gene for the variable region into a host cell. Activity of Ianalumab Biosimilar The primary function of Ianalumab Biosimilar is to bind to the TNFRSF13C protein, which is found on the surface of immune cells called B cells. This binding prevents the TNFRSF13C protein from interacting with its natural ligands, BAFF and APRIL, which are essential for the survival and proliferation of B cells. By inhibiting the activity of TNFRSF13C, Ianalumab Biosimilar reduces the number of B cells in the body, which can be beneficial in autoimmune diseases where there is an overactive immune response. Additionally, the antibody may also modulate the production of antibodies by B cells, further regulating the immune response. Application of Ianalumab Biosimilar Ianalumab Biosimilar has the potential to be used in the treatment of various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjogren’s syndrome. These diseases are characterized by an overactive immune response, and the targeting of TNFRSF13C with Ianalumab Biosimilar can help to regulate this response and reduce the symptoms of the disease. In addition to its potential therapeutic applications, Ianalumab Biosimilar can also be used as a research tool in the study of B cell biology and the immune system. The specificity of the antibody for TNFRSF13C makes it a valuable tool for studying the role of this protein in various diseases and in normal immune function. Conclusion In summary, Ianalumab Biosimilar is a fully humanized monoclonal antibody that targets the TNFRSF13C protein. Its specific binding to this protein allows for the modulation of the immune response, making it a potential treatment option for autoimmune diseases. Additionally, the antibody can also be used as a research tool in the study of B cell biology. With its promising therapeutic and research applications, Ianalumab Biosimilar has the potential to make a significant impact in the field of immunology.

Ibalizumab Biosimilar – Anti-CD4 D3 domain mAb – Research Grade, ProteoGenix, PX-TA1174

Description of Ibalizumab Biosimilar - Anti-CD4 D3 domain mAb - Research Grade Introduction Ibalizumab Biosimilar, also known as Anti-CD4 D3 domain mAb, is a monoclonal antibody that targets the CD4 receptor on immune cells. This biosimilar is currently being developed as a potential therapeutic option for various diseases, particularly HIV/AIDS. In this article, we will explore the structure, activity, and potential applications of Ibalizumab Biosimilar in the field of medicine. Structure of Ibalizumab Biosimilar Ibalizumab Biosimilar is a recombinant humanized IgG4 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Ibalizumab Biosimilar is responsible for binding to the CD4 receptor, while the constant region determines the antibody’s effector functions. Activity of Ibalizumab Biosimilar The primary function of Ibalizumab Biosimilar is to inhibit the interaction between the CD4 receptor and the HIV envelope protein, gp120. This interaction is essential for HIV to enter and infect immune cells. By blocking this interaction, Ibalizumab Biosimilar prevents HIV from replicating and spreading, thereby reducing the viral load in the body. Additionally, Ibalizumab Biosimilar has been shown to have a unique mechanism of action compared to other anti-HIV drugs. It binds to a different site on the CD4 receptor, known as the D3 domain, which is not targeted by other HIV therapies. This makes Ibalizumab Biosimilar a potential option for patients who have developed resistance to other anti-HIV drugs. Applications of Ibalizumab Biosimilar Ibalizumab Biosimilar is currently being studied as a potential treatment for HIV/AIDS. It has shown promising results in clinical trials, with some patients achieving undetectable viral loads after treatment with Ibalizumab Biosimilar. This makes it a potential option for patients who have failed to respond to other anti-HIV therapies. Apart from HIV, Ibalizumab Biosimilar has also shown potential in the treatment of other diseases. It has been studied in animal models for its potential use in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Additionally, Ibalizumab Biosimilar has also been investigated for its potential to prevent organ rejection in transplant patients. Research Grade Ibalizumab Biosimilar Ibalizumab Biosimilar is currently in the research grade stage, which means it is being studied and evaluated for its safety and efficacy in treating diseases. This is a crucial step in the development of any new drug, as it helps to determine the appropriate dosage, potential side effects, and overall effectiveness of the medication. Conclusion In conclusion, Ibalizumab Biosimilar is a promising monoclonal antibody that targets the CD4 receptor and has shown potential in the treatment of HIV/AIDS and other diseases. Its unique mechanism of action and potential for use in patients who have developed resistance to other drugs make it a valuable addition to the current arsenal of anti-HIV therapies. As research on Ibalizumab Biosimilar continues, it may prove to be a valuable therapeutic option for various diseases, providing hope for patients and healthcare providers alike.